The unusual actinomycetes strain No. E465-94 produced a complex of new glycopeptide antibiotics tallysomycin, which was separated by CM-Sephadex chromatography into two major components, A (C68H107N21O27S2) and B (C62H95N19O26S2). They were isolated first in a copperchelated form and showed physico-chemical properties similar to those of the bleomycingroup of antibiotics. Tallysomycin exhibited broad antibacterial and antifungal activity, and was highly active in vivo against bacterial infections in mice. Tallysomycins A and B demonstrated potent activity in the prophage induction of lysogenic bacteria.
The unusual actinomycetes strain No. E465-94 produced a complex of new glycopeptide antibiotics tallysomycin, which was separated by CM-Sephadex chromatography into two major components, A (C68H107N21O27S2) and B (C62H95N19O26S2). They were isolated first in a copperchelated form and showed physico-chemical properties similar to those of the bleomycingroup of antibiotics. Tallysomycin exhibited broad antibacterial and antifungal activity, and was highly active in vivo against bacterial infections in mice. Tallysomycins A and B demonstrated potent activity in the prophage induction of lysogenic bacteria.
In the course of our search for new antibiotics produced by rare actinomycetes strains, an organism designated as strain No. E465-94 in our culture collection was isolated from an Indian soil sample.
It showed Streptomyces-like morphology but had an unusual type of cell-wall composition. Shaking or stir jar fermentation of strain E465-94 produced a new water-soluble basic antibiotic complex named tallysomycin, which was extracted from the broth filtrate by an ion-exchange resin process and separated into two major components, tallysomycins A and B. They were first isolated in copper-chelated form and degradation studies indicated a glycopeptide structure for both components.
As reported in a companion paper1), tallysomycins A and B have the same chromophore as bleomycin but differ from the latter in the amino acid composition and the presence of an additional unique sugar moiety, 4-amino-4,6-dideoxy-L-talose. Tallysomycin inhibited the growth of various bacteria and fungi and showed strong induction activity in lysogenic bacteria. Strain E465-94 also produced, along with tallysomycin components, an aminoglycoside antibiotic complex which was identified as nebramycin factors5).
This paper reports the production, isolation, physico-chemical and biological properties of tallysomycins A and B. Detailed descriptions of the producing organism" and the antitumor activity3,4) of tallysomycins A and B will be reported separately.
Producing Organism
The actinomycetes strain No. E465-94 produced tufts of spore chains as well as single spore chains in the aerial mycelium. The spores showed smooth surface structure and were oval to short cylindrical in shape.
In addition, small sporangium-like bodies were occasionally observed. The spore chain morphology of strain E465-94 is very similar to that reported for some Streptomyces species (e.g. S.
* This antibiotic was originally designated Bu-2231 .
E465-94 was found to contain meso-a,_--diaminopimelic acid (meso-DAP) instead of LL-diaminopimelic acid which has been thought to be a key component in the cell wall of Streptomyces and related genera.
In addition, the cell wall of strain E465-94 contained galactose, mannose and rhamnose as diagnostic carbohydrate components. Detailed descriptions of the morphological, cultural and physiological characteristics, cell-wall composition and taxonomy will be published elsewhere".
Antibiotic Production
A well-grown agar slant of the actinomycetes strain E465-94 was used to inoculate vegetative medium containing 1.5%. glucose, 0.2% yeast extract, 0.5 % Polypeptone, 0.05% , K2HPO4, 0.05%
MgSO4.7H2O and 0.5% CaCO3, the pH being adjusted to 7.2 before sterilization. The seed culture was incubated at 33°C for 48 hours on a rotary shaker (250 rpm), and 5 nil of the growth was transferred to a 500-nil Erlenmeyer flask containing 100 nil of fermentation medium composed of 2 % glycerol, 1 % Pharmamedia, I % cornsteep liquor, 0.3 % (NH4)2SO4, 0.003% ZnS04-7H2O and 0.4%, CaCO3.
Antibiotic activity in the fermentation broth was determined by paper disc agar-diffusion assay using
Bacillus subtilis PCI 219 and Mycobacterium smeginatis strain M6-3* as test organisms. Tallysomycin components and the co-produced nebramycin factors were all active against B. subtili.s but only tallysomycin components showed activity against the mycobacterial strain M6-3. The broth pH gradually rose with the progress of fermentation and reached 7.5-7.7 after 120~130 hours when a peak antibiotic potency of 300 mcg/ml was obtained.
Isolation and Purification
The harvested broth was filtered with filter aid and the bioactivity in the filtrate (65 liters, pH 7)
was adsorbed on a column of Amberlite IRC-50 (NH4 + form, 7 liters). Fig. 3 . NMR spectrum of tallysomycin A (60 MHz, in D2O).
Fig. 4. NMR spectrum of tallysomycin B (60 MHz, in D2O).
As shown in Table 1 , the analytical data for tallysomycins A and B, both analyzed as formates, agreed with the molecular formula of C68H107N21O2;S2 and C62H95N19O26S2, respectively, indicating a difference of six-carbons between the two components, which however was firmly established only after the elucidation of the structures.1) The specific rotation and UV spectral data of tallysomycins A and B are also shown in Table 1 . The ratio of absorbancies at 240 nm and 290 nm for components A and B
(1.28 and 1.31, respectively) suggested that tallysomycins A and B belong to the bleomycin group of antibiotics rather than the phleomycin group. Detection by ninhydrin reagent and UV light. ** S-102 : MeOH -10% NH4OAc (1: 1) .
S-123 : MeOH -10% NH4OAc -10%. NH4OH (10: 9 : 1). Table 2 . System S-102 was found useful to separate by TLC the copper-free tallysomycin components from the corresponding copper-chelated forms.
Biological Properties
Tallysomycins A and B showed potent antimicrobial activity against various types of bacteria and fungi. The minimum inhibitory concentrations (MIC) of tallysomycins A and B against gram-positive , gram-negative and acid-fast bacteria were determined in nutrient agar by the two-fold agar dilution method using a STEERS' multi-inoculating apparatus.8) Bleomycin complex consisting mainly of bleomycin A2 component was used as a reference in these in vitro tests. As shown in Table 3 , the antibacterial activity of tallysomycin A was in general 2-4 times greater than that of tallysomycin B, except for acid-fast bacteria which showed the same susceptibility to both components. Tallysomycins A and B were significantly more active than bleomycin and some bacterial strains which were not sensitive to bleomycin, such as Pseudomonas aeruginosa and Proteus morganii, were inhibited by tallysomycin components. Anaerobic bacteria were not inhibited by tallysornycins A and B (MIC: >100 mcg/ml) when tested by agar dilution method on GAM medium (Nissui, Tokyo).
The antifungal activities of tallysomycins A and B were determined by the two-fold agar dilution method in SABOURAUD agar medium against a variety of yeasts and fungi. The results are shown in Table 4 . In contrast to the antibacterial activity, the antifungal activity of tallysomycin B was about 2-4 times greater than that of tallysomycin A. Bleomycin showed rather weak and limited activity against yeasts and fungi. The antibacterial activity of tallysomycin was also demonstrated in vivo against experimental infections in mice. The pathogenic bacteria used for the in vivo test were S. aureus Smith, E. co/i Juhl and P. aeruginosa A9843. Mice were challenged with a 100 x LD50 dose of the pathogens in a 5 % suspension of hog gastric mucin (American Laboratories, Omaha, Neb.) and a single subcutaneous treatment with the antibiotic was made immediately after the bacterial challenge. A group of 5 mice was used for each dosage level and the animals were observed for 5 days to determine the median protective dose (PD$o). As shown in Table 5 , tallysomycins A and B demonstrated very potent in vivo activity against the bacterial infections.
The activity of prophage induction in lysogenic bacterium, E. co/i W1709 (A), was determined for tallysomycins A and B according to the method of LEIN et al.17) The plaque count was made on agar plates containing test material (T) and control plate (C). A T/C ratio of the plaque counts of greater than 3 was considered significant and the lysogenic induction activity (ILB activity) was expressed by the minimum inducing concentration of the test compound.
As shown in Table 6 , the ILB activity of tallysomycin A was about 8 times higher than that of tallysomycin B which was in turn 4 times more potent than bleomycin.
Tallysomycins A and B showed antitumor activity in experimental animal tumor systems including lymphocytic leukemia P-388, sarcoma 180, LEwis lung carcinoma, WALKER carcinosarcoma 256 and melanoma B-16. The antitumor activity of tallysomycins will be reported in detail separately .3,4)
The acute toxicity of tallysomycins A and B was determined in mice by a single administration by Table 7 .
In terms of LD50 values, tallysomycin A was about twice more toxic than tallysomycin B by a single ip or iv administration but less so in the multiple ip dosing schedule. Bleomycin was significantly less toxic than tallysomycins A and B.
Discussion
The physico-chemical and biological properties of tallysomycins A and B described in the present paper indicated close similarities to those of the pheeomycin9) and bleomycin10) families of antibiotics which include zorbamycin,11) zorbonomycins B and C,11) YA-56 X and Y,12) victomycin,13) and platomycins A and B.14) The ratio of absorbancies at 240 nm and 290 nm for tallysomycins A and B (ea. Table 8 . A number of bleomycin components10,16) reported to date are different from tallysomycins A and B in the glycopeptide skeleton as described in a companion paper1). 
